Alidad Mireskandari, President and COO of Niki BioSolutions, Inc. (NASDAQ:NIKI), filed a Form 4 on November 17, 2026, disclosing grants of 20,000 restricted stock units and 80,000 stock options dated July 22, 2026.
Key Highlights
- RSU grant: Mireskandari received 20,000 restricted stock units on July 22, 2026, each representing a contingent right to receive one share of common stock, and all 20,000 RSUs vested on that same date.
- Stock option grant: 80,000 stock options were granted on July 22, 2026, with an exercise price of $8.83 and an expiration date of July 22, 2036.
- Post-transaction holdings: Following the RSU settlement, the filing reports 20,000 shares of common stock beneficially owned directly; 80,000 stock options remain outstanding.
- Multi-tranche vesting: The 80,000 options vest across six separate conditions, including time-based quarterly installments and performance-based milestones.
- Transaction code: Both grants carry transaction code "M" (RSU settlement) and "A" (acquisition) as reported in the filing.
- Reporting person role: Mireskandari is identified in the filing as President and Chief Operating Officer of Niki BioSolutions, Inc.
RSU Settlement and Option Grant Details for Mireskandari at Niki BioSolutions
According to the filing, Alidad Mireskandari was granted 20,000 restricted stock units on July 22, 2026, each of which "represents a contingent right to receive, upon settlement, one share of Common Stock." The filing states that all 20,000 RSUs vested on that same date, and following settlement, the reporting person directly held 20,000 shares of common stock. No price was paid for the RSU award, as the filing records a price of $0 for the derivative security.
The filing also discloses that Mireskandari received 80,000 stock options on July 22, 2026, with an exercise price of $8.83 per share and an expiration date of July 22, 2036. As described in the filing's explanation of responses, the options vest under six distinct conditions: (i) 40,000 options vest in eight equal quarterly installments; (ii) 5,000 vest upon completion and publication of the clinical validation study of CogniMIR to meet CLIA requirements; (iii) 10,000 vest upon the company entering into a biopharmaceutical services, collaboration, or partnership agreement resulting in proceeds of at least $250,000; (iv) 5,000 vest upon the company generating $1,000,000 in revenue; (v) 10,000 vest upon completion of capital raises totaling $5,000,000; and (vi) 10,000 vest upon a 100% increase in the company's stock price following the closing of the merger that the filing states occurred in July 2026.
The filing reports that 80,000 stock options are beneficially owned directly following the reported transaction, with no derivative securities disposed of. All reported transactions were filed by one reporting person, and the form bears the signature of Alidad Mireskandari dated November 17, 2026.
What Was Disclosed
Alidad Mireskandari, President and COO of Niki BioSolutions, disclosed grants of 20,000 RSUs (all vested on grant date) and 80,000 stock options at $8.83, both dated July 22, 2026, with multi-condition vesting terms for the options.




Please wait processing your request...